Tough times for clinical trials, but a positive transformation of data use seen

2 July 2021

Arkivum, a University of Southampton spin-out, has just published a new report - “ Good data in the age of digital transformation” - tracking the progress of 300 global life sciences and biopharma companies over the past year as they implement digital transformation strategies and unlock the potential of their clinical trial data.

After the havoc of COVID-19, ambitious strategies for digital transformation are seen as a wise investment as life sciences organizations upgrade their capacities for managing clinical trials and the valuable scientific and regulatory data they generate.

This is Arkivum’s second annual report, the key findings of which are as follows:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK